| Original language | English (US) |
|---|---|
| Pages (from-to) | 195-197 |
| Number of pages | 3 |
| Journal | The Lancet Oncology |
| Volume | 23 |
| Issue number | 2 |
| DOIs |
|
| State | Published - Feb 2022 |
ASJC Scopus subject areas
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The Lancet Oncology, Vol. 23, No. 2, 02.2022, p. 195-197.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
AU - Pfeiler, Georg
AU - DeMichele, Angela
AU - Dueck, Amylou C.
AU - Fesl, Christian
AU - Gnant, Michael
AU - Mayer, Erica L.
N1 - Funding Information: GP reports personal fees from Novartis, Roche, AstraZeneca, Eli Lilly, and Amgen; and grants and personal fees from Pfizer, outside the submitted Comment. AD reports grants from the Alliance Foundation for Clinical Trials, during the conduct of the study; personal fees from Pfizer and Context Therapeutics; grants from Novartis, Pfizer, Genentech, Calithera, and Johnson and Johnson, outside the submitted Comment; and that their spouse is on a data safety monitoring board for a Pfizer drug not for use in oncology. CF reports grants from Pfizer, during the conduct of the study. MG reports personal fees from Amgen, Daiichi Sankyo, AstraZeneca, Eli Lilly, LifeBrain, Nanostring, Novartis, and TLC Biopharmaceuticals, all outside the submitted Comment; and that an immediate family member is employed by Sandoz. ELM reports personal fees from Eisai, Eli Lilly, and Novartis, outside the submitted work. ACD declares no competing interests. We received support from Alliance Foundation Trials, Austrian Breast and Colorectal Cancer Study Group, and the Breast International Group. The trial (including these analyses) was funded by Pfizer, who provided the study drug and financial support.
PY - 2022/2
Y1 - 2022/2
UR - http://www.scopus.com/inward/record.url?scp=85123760309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123760309&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(21)00708-7
DO - 10.1016/S1470-2045(21)00708-7
M3 - Comment/debate
C2 - 35114114
AN - SCOPUS:85123760309
SN - 1470-2045
VL - 23
SP - 195
EP - 197
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 2
ER -